Ivosidenib for IDH1‐Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real‐World Study

This study suggests that ivosidenib is a valid option for patients affected by metastatic IDH1 mutant CCA after at least one line of standard treatment.

Authors

Institutions

Publication Details

Journal
Liver International
Published
2025-08-26
DOI
https://doi.org/10.1111/liv.70295
Primary Topic
Cholangiocarcinoma and Gallbladder Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ivosidenib for IDH1‐Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real‐World Study

P. Cito, Lorenzo Antonuzzo, Silvia Foti, Silvia Camera et al.
Liver International
Cholangiocarcinoma and Gallbladder Cancer Studies
article

Ivosidenib for IDH1‐Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real‐World Study

P. Cito, Lorenzo Antonuzzo, Silvia Foti, Silvia Camera, Eduardo Terán‐Brage, Tiziana Pressiani, Margherita Rimini, Alessandro Pastorino, Monica Niger, Mara Persano, Anna Melzer, Lukas Perkhofer, Florian Castet, Tiziana Saladino, Sara Lonardi, Mario Domenico Rizzato, Vincenzo Mazzaferro, Thomas J. Ettrich, Daniele Lavacchi, Chiara Pircher, Filippo Pietrantonio, Teresa Macarulla, Narejos Pérez Silvia, Giuseppe Aprile, Carolina Sciortino, Andrea Casadei‐Gardini, Lorenza Rimassa, Kreina Sharela Vega, Torsello Angela
article en

Abstract

This study suggests that ivosidenib is a valid option for patients affected by metastatic IDH1 mutant CCA after at least one line of standard treatment.

Liver InternationalVol. 45(9)
University of Udine (IT), Humanitas University (IT), Vita-Salute San Raffaele University (IT), University of Milan (IT), Azienda Ospedaliera San Giovanni Addolorata (IT), Città di Castello Hospital (IT), Istituto Oncologico Veneto (IT), Azienda Ospedaliero-Universitaria Careggi (IT), Vall d'Hebron Hospital Universitari (ES), Ospedale Policlinico San Martino (IT), Fondazione Poliambulanza Istituto Ospedaliero (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), University Hospital Ulm (DE), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), IRCCS Humanitas Research Hospital (IT), University of Macerata (IT)
Openalex Percentile: Top 64%
Cholangiocarcinoma and Gallbladder Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.